You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

 

Online download statistics by month:

Online download statistics by month: June 2022 to August 2025

AbstractFullPdf
Jun 202226927055
Jul 2022351353131
Aug 202214414448
Sep 202210911349
Oct 202215515649
Nov 2022216218108
Dec 202212512558
Jan 202314114276
Feb 2023167169127
Mar 202316816973
Apr 202312713168
May 202310610845
Jun 202311411461
Jul 202311612352
Aug 2023989962
Sep 2023979767
Oct 202311411446
Nov 2023919169
Dec 2023979758
Jan 2024142143105
Feb 202410110151
Mar 2024153156174
Apr 202411911973
May 202411711994
Jun 2024124127114
Jul 2024143145119
Aug 202411711896
Sep 20241141151062
Oct 2024140141121
Nov 202413113290
Dec 2024152153126
Jan 202515915995
Feb 2025290291127
Mar 2025157157114
Apr 2025179179133
May 2025127129106
Jun 2025575845
Jul 2025110
Aug 2025110
Total532953774147